NASDAQ:CARM Carisma Therapeutics (CARM) Stock Price, News & Analysis $0.94 -0.03 (-3.52%) (As of 05:35 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends About Carisma Therapeutics Stock (NASDAQ:CARM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Carisma Therapeutics alerts:Sign Up Key Stats Today's Range$0.93▼$0.9950-Day Range$0.88▼$1.1152-Week Range$0.80▼$3.16Volume101,472 shsAverage Volume341,680 shsMarket Capitalization$39.20 millionP/E RatioN/ADividend YieldN/APrice Target$7.00Consensus RatingBuy Company OverviewCarisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.Read More… Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners (Ad)Trump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…Get Your Free Gold Guide Carisma Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks66th Percentile Overall ScoreCARM MarketRank™: Carisma Therapeutics scored higher than 66% of companies evaluated by MarketBeat, and ranked 392nd out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingBuy Consensus RatingCarisma Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCarisma Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Carisma Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Carisma Therapeutics are expected to grow in the coming year, from ($1.33) to ($1.26) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Carisma Therapeutics is -0.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Carisma Therapeutics is -0.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Carisma Therapeutics' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.00% of the float of Carisma Therapeutics has been sold short.Short Interest Ratio / Days to CoverCarisma Therapeutics has a short interest ratio ("days to cover") of 5.9.Change versus previous monthShort interest in Carisma Therapeutics has recently decreased by 18.33%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCarisma Therapeutics does not currently pay a dividend.Dividend GrowthCarisma Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted4.00% of the float of Carisma Therapeutics has been sold short.Short Interest Ratio / Days to CoverCarisma Therapeutics has a short interest ratio ("days to cover") of 5.9.Change versus previous monthShort interest in Carisma Therapeutics has recently decreased by 18.33%, indicating that investor sentiment is improving significantly. News and Social Media2.6 / 5News Sentiment0.63 News SentimentCarisma Therapeutics has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Carisma Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for CARM on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows2 people have added Carisma Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Carisma Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders12.57% of the stock of Carisma Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions44.27% of the stock of Carisma Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Carisma Therapeutics' insider trading history. Receive CARM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Carisma Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CARM Stock News HeadlinesOptimistic Buy Rating for Carisma Therapeutics Amid Promising CAR-Myeloid Developments and Strong Financial StandingNovember 12 at 2:43 AM | markets.businessinsider.comCarisma Therapeutics Reports Q3 2024 Results, Advances Clinical ProgramsNovember 12 at 2:43 AM | msn.comTrump’s Back, but DC’s Coming for Your Money!Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy with a heavy hand—building up infrastructure, slapping tariffs on imports, and going all-in on U.S. jobs. But here's the kicker: while Trump's focused on making America stronger, the Washington elite is ready to fight back…November 14, 2024 | Genesis Gold Group (Ad)Evercore ISI Remains a Buy on Carisma Therapeutics (CARM)November 10, 2024 | markets.businessinsider.comCarisma Therapeutics reports data from its CAR-M therapyNovember 8, 2024 | markets.businessinsider.comCarisma Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular CarcinomaNovember 8, 2024 | prnewswire.comCarisma Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business HighlightsNovember 7, 2024 | prnewswire.comCarisma to present new data on CAR-M therapy for hepatocellular carcinomaNovember 5, 2024 | markets.businessinsider.comSee More Headlines CARM Stock Analysis - Frequently Asked Questions How have CARM shares performed this year? Carisma Therapeutics' stock was trading at $2.93 at the start of the year. Since then, CARM stock has decreased by 68.0% and is now trading at $0.9389. View the best growth stocks for 2024 here. How were Carisma Therapeutics' earnings last quarter? Carisma Therapeutics, Inc. (NASDAQ:CARM) announced its quarterly earnings data on Thursday, November, 7th. The company reported ($0.31) EPS for the quarter, meeting analysts' consensus estimates of ($0.31). The company earned $3.39 million during the quarter. Carisma Therapeutics had a negative net margin of 314.78% and a negative trailing twelve-month return on equity of 957.20%. How do I buy shares of Carisma Therapeutics? Shares of CARM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Carisma Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Carisma Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), Broadcom (AVGO) and Palo Alto Networks (PANW). Company Calendar Last Earnings11/07/2024Today11/14/2024Fiscal Year End12/31/2024Next Earnings (Estimated)4/07/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CARM CUSIPN/A CIK1485003 WebN/A Phone617-444-8550Fax617-858-0911Employees20Year FoundedN/APrice Target and Rating Average Stock Price Target$7.00 High Stock Price Target$8.00 Low Stock Price Target$6.00 Potential Upside/Downside+619.3%Consensus RatingBuy Rating Score (0-4)3.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.56) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-86,880,000.00 Net Margins-314.78% Pretax Margin-315.75% Return on Equity-957.20% Return on Assets-96.39% Debt Debt-to-Equity Ratio1.39 Current Ratio3.23 Quick Ratio3.23 Sales & Book Value Annual Sales$14.92 million Price / Sales2.72 Cash FlowN/A Price / Cash FlowN/A Book Value($0.27) per share Price / Book-3.60Miscellaneous Outstanding Shares41,750,000Free Float36,502,000Market Cap$40.63 million OptionableNo Data Beta1.49 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report This page (NASDAQ:CARM) was last updated on 11/14/2024 by MarketBeat.com Staff From Our PartnersBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredTrump’s Back, but DC’s Coming for Your Money!Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThis small cap’s electric marine powertrain broke the world speed recordThe future of marine propulsion has arrived-powered by a $2 billion powerhouse. In collaboration with McLar...The Tomorrow Investor | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | SponsoredThe next assassination attempt won’t be on TrumpPresident Trump is soon to be back in the White House. Unity has been restored to the U.S. But if you wa...Porter & Company | SponsoredElon Musk’s $30 Billion Trump Bet Pays Off—What’s Next?Elon Musk bet big on Trump's victory, and that gamble has already added over $30 billion to his net worth in a...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Carisma Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Carisma Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.